# Ceramide NanoLiposome in Patients With Advanced Solid Tumors

> **NCT02834611** · PHASE1 · COMPLETED · sponsor: **Keystone Nano, Inc** · enrollment: 14 (actual)

## Conditions studied

- Cancer
- Carcinoma
- Solid Tumors
- Tumor

## Interventions

- **DRUG:** Ceramide NanoLiposome

## Key facts

- **NCT ID:** NCT02834611
- **Lead sponsor:** Keystone Nano, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2023-08-03
- **Final completion:** 2023-11-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-05-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02834611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02834611, "Ceramide NanoLiposome in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02834611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*